SANGUI BIOTECH INTERNATIONAL INC: Nasdaq/NYSE listing notice — Sangui BioTech delisted from OTCQB to Pink Market after failing $0.01 bid-price rule

SANGUI BIOTECH INTERNATIONAL INC

OTC Markets commenced delisting from OTCQB for non-compliance with minimum closing bid price of $0.01 per share for 30 days.
Effective November 2, 2022, common stock moved to the Pink Market and continues to trade under symbol 'SGBI'.
Company intends to maintain current SEC reporting obligations despite the transfer.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

SANGUI BIOTECH INTERNATIONAL INC received a otc delisting notice notice regarding minimum bid price.

Exchange: otc
Notice: delisting notice
Deficiency: minimum bid price

Exact text from the filing

October 31, 2022, Sangui BioTech International, Inc. (the “Company” or “Sangui”) was notified by the OTC Markets Group (the “OTC”) that the OTC had determined to commence proceedings to delist its common stock (the “Common Stock”) from the OTCQB as a result of the Company’s failure to comply with the continued listing standard set forth in the OTCQB Standards, Section 2.3(2) which states that the company must “maintain proprietary priced quotations published by a Market Maker in OTC Link with a minimum closing bid price of $.01 per share on at least one of the prior thirty consecutive calendar

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001551163-22-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.